Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
No patent data available. Pre-approval drugs may not have Orange Book listings.
Replagal
Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).
View on EMAMyelodysplastic Syndrome
Type 2 Diabetes Mellitus
Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Disease
Hypertension